Strides Arcolab’s wholly owned subsidiary - Onco Therapies, has received USFDA approvals for Cisplatin Injection, 1 mg/mL packages in 50 mL and 100 mL multiple dose vials. Cisplatin is amongst the products in the drug shortage list of USFDA. According to IMS data, the US market for generic Cisplatin is approximately $10 million.
Cisplatin is part of the oncology portfolio licensed to Pfizer in January 2010 for the US market and expected to be launched shortly. Cisplatin is a chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas, and germ cell tumors.
Strides Arcolab is a global pharmaceuticals headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceuticals products with an emphasis on sterile injectables.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.50 |
| Dr. Reddys Lab | 1233.20 |
| Cipla | 1232.00 |
| Zydus Lifesciences | 937.70 |
| Lupin | 2327.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: